Arcutis grants 57,000 RSUs under Nasdaq Rule 5635(c)(4)
Arcutis Biotherapeutics announced the grant of an aggregate 57,000 restricted stock units (RSUs) under Nasdaq Listing Rule 5635(c)(4).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.